Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ETBOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and ...
FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against ...
ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...
Power Metals entered into a cesium concentrate offtake agreement with Albemarle Corporation, a US$16 billion global critical ...
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation ...
Phase 3 findings show oral zoliflodacin to be non-inferior to the combination of ceftriaxone and azithromycin for the ...
Solutions Market Overview:The global electronic clinical outcome assessment (eCOA) solutions market is expected to grow at a ...
Quincey to Continue as Executive Chairman of the BoardATLANTA--(BUSINESS WIRE)--The Coca-Cola Company today announced that ...
Leadership Changes to Take Effect Following Conclusion of Ordinary General Meeting of Shareholders in March 2026Announcement ...
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first ...
Antin Infrastructure Partners (Paris:ANTIN) has agreed to acquire NorthC Datacenters, a leading enterprise colocation data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback